At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Trading 01-15 13:59:17
122.000
-1.400
-1.13%
High126.800Low121.300Vol2.32M
Open124.600D1 Closing123.400Amplitude4.46%
Mkt Cap112.36BTradable Cap112.36BTotal Shares921.00M
T/O287.15MT/O Rate0.25%Tradable Shares921.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study
Reuters  ·  01-14 11:54
Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study
Zhutong Hong Kong Stock Connect Active Trading | January 13
Stock News  ·  01-13 19:14
Zhutong Hong Kong Stock Connect Active Trading | January 13
Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)
Stock News  ·  01-08
Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)
HK Stock Movement | AKESO (09926) Rises Over 6% Again as Ivonescimab Labeling Receives Major Update Including AK112-301 Study Results
Stock News  ·  01-07
HK Stock Movement | AKESO (09926) Rises Over 6% Again as Ivonescimab Labeling Receives Major Update Including AK112-301 Study Results
Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial
Reuters  ·  01-07
Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial
HK Movers | Innovative Drug Stocks Jump With TYK Medicines up 14%
Tiger Newspress  ·  01-07
HK Movers | Innovative Drug Stocks Jump With TYK Medicines up 14%
Asian Stocks That Could Be Trading Below Their Estimated Value
Simply Wall St.  ·  01-01
Asian Stocks That Could Be Trading Below Their Estimated Value
The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial
Simply Wall St.  ·  2025-12-17
The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial
FIRST SHANGHAI Initiates "Buy" Rating on AKESO (09926) with Target Price of HK$144.9
Stock News  ·  2025-12-15
FIRST SHANGHAI Initiates "Buy" Rating on AKESO (09926) with Target Price of HK$144.9
Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
Deep News  ·  2025-12-15
Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
AKESO Surges 6.8% After Major Announcement; Innovative Drug Leaders Rally, High-Beta HKSC Innovative Drug ETF (520880) Reverses Losses to Gain Over 1%
Deep News  ·  2025-12-12
AKESO Surges 6.8% After Major Announcement; Innovative Drug Leaders Rally, High-Beta HKSC Innovative Drug ETF (520880) Reverses Losses to Gain Over 1%
HK Stock Movement | AKESO (09926) Rises Over 3% Again as FDA Approves Global Phase III Trial for Cadonilimab in First-Line Gastric Cancer Treatment
Stock News  ·  2025-12-12
HK Stock Movement | AKESO (09926) Rises Over 3% Again as FDA Approves Global Phase III Trial for Cadonilimab in First-Line Gastric Cancer Treatment
FDA Clears Akeso Inc. to Begin Global Phase III Trial of Cadonilimab in First-Line Gastric Cancer
Reuters  ·  2025-12-12
FDA Clears Akeso Inc. to Begin Global Phase III Trial of Cadonilimab in First-Line Gastric Cancer
Cadonilimab (Pd-1/Ctla-4) Receives FDA Clearance for Global Phase Iii First-Line Gastric Cancer Trial Versus Nivolumab
THOMSON REUTERS  ·  2025-12-12
Cadonilimab (Pd-1/Ctla-4) Receives FDA Clearance for Global Phase Iii First-Line Gastric Cancer Trial Versus Nivolumab
HK Stock Movement | AKESO (09926) Rises Over 3% in Early Trading as Updated Data on Ivonescimab for First-Line TNBC Treatment Released at ESMO IO 2025
Stock News  ·  2025-12-11
HK Stock Movement | AKESO (09926) Rises Over 3% in Early Trading as Updated Data on Ivonescimab for First-Line TNBC Treatment Released at ESMO IO 2025
Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial
Reuters  ·  2025-12-11
Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial
BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs
Stock News  ·  2025-12-10
BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs
Assessing Akeso (SEHK:9926) After Its Strong Year-to-Date Rally and Recent Share Price Pullback
Simply Wall St.  ·  2025-12-10
Assessing Akeso (SEHK:9926) After Its Strong Year-to-Date Rally and Recent Share Price Pullback
Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer
Reuters  ·  2025-12-09
Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer
Hong Kong Stock Connect Innovative Drug Sector Accelerates Decline in Afternoon, AKESO Drops Over 5%! Pure Innovative Drug ETF "520880" Falls Over 2% as Premium Surges
Deep News  ·  2025-12-09
Hong Kong Stock Connect Innovative Drug Sector Accelerates Decline in Afternoon, AKESO Drops Over 5%! Pure Innovative Drug ETF "520880" Falls Over 2% as Premium Surges

Introduction

Company Name.
AKESO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Issue price:
--